IDH inhibitors, like ivosidenib and enasidenib, offer a targeted approach to reverse the inhibitory effect of 2-HG, an oncometabolite that accumulates in IDH-mutant cancers and inhibits TET enzymes, thereby restoring 5hmC levels and potentially improving outcomes, particularly in IDH-mutant AML [12, 53, 85]. Combination epigenetic therapies, such as using hypomethylating agents in combination with histone deacetylase inhibitors, are being investigated for their potential to reshape the cancer epigenome and improve treatment responses. The gene discussed is IDH2; the disease is acute myeloid leukemia.